Alpha mannosidosis is a rare inherited disorder in which the body lacks a functional enzyme needed to break down certain sugar molecules inside cells. With a global incidence of roughly 1 in 785,000 live births, it affects multiple organ systems and ranges widely in severity, from a mild form recognized in adolescence to a severe form that can be fatal in early childhood. The condition is progressive, but treatments including enzyme replacement therapy and stem cell transplants are changing outcomes for many patients.
What Causes Alpha Mannosidosis
The disorder traces back to mutations in a single gene called MAN2B1, which provides the blueprint for an enzyme called alpha-mannosidase. This enzyme works inside lysosomes, the recycling centers of cells, where it breaks down sugar chains (oligosaccharides) that contain mannose. When the enzyme is missing or defective, those sugar chains pile up in lysosomes throughout the body, eventually causing cells to malfunction and die.
More than 120 different mutations in the MAN2B1 gene have been identified. Some swap a single building block in the enzyme’s structure; others produce a shortened or incorrectly assembled version. All of them impair the enzyme’s ability to do its job. The resulting buildup of oligosaccharides damages tissues and organs over time, producing the wide range of symptoms associated with the disease.
Alpha mannosidosis follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy of the gene from each parent to develop the condition. Parents who each carry one defective copy typically have no symptoms themselves.
Three Clinical Types
Doctors generally classify untreated alpha mannosidosis into three types based on when symptoms appear and how quickly the disease progresses. Most people diagnosed fall into the moderate category.
- Mild (type 1): Recognized after age ten. Involves muscle weakness with slow progression and no significant skeletal abnormalities.
- Moderate (type 2): Recognized before age ten. Includes muscle weakness, slow progression, and skeletal abnormalities such as joint deterioration or spinal deformities.
- Severe (type 3): Progresses quickly, with significant nervous system involvement or life-threatening infections in early childhood.
These categories are useful as a general framework, but alpha mannosidosis exists on a spectrum. Two people with the same type can experience noticeably different symptoms and timelines.
Symptoms and Physical Features
Because the sugar buildup affects cells throughout the body, alpha mannosidosis can produce a wide variety of symptoms. Intellectual disability is common and varies from mild to severe. Many affected individuals have distinctive facial features: a large head with a prominent forehead, low hairline, rounded eyebrows, large ears, a flattened nasal bridge, a protruding jaw, widely spaced teeth, overgrown gums, and a large tongue.
Skeletal problems are frequent in the moderate and severe forms. These include reduced bone density, thickening of the skull bones, spinal deformities, knock knees, and progressive deterioration of joints. Muscle weakness often accompanies these changes, and children may be slow to reach motor milestones like sitting and walking.
Hearing loss is one of the most consistent features, affecting the large majority of patients. Clouding of the eye’s lens (cataracts) can also develop. Many individuals experience repeated infections, and some develop an enlarged liver and spleen or a buildup of fluid around the brain. Speech impairments and difficulty coordinating movements are common as well.
A less widely recognized feature is psychiatric vulnerability. Some people with alpha mannosidosis develop depression, anxiety, or hallucinations, and these episodes can be triggered by stressors like surgery, emotional upset, or changes in daily routine.
How It Is Diagnosed
Diagnosis typically starts when a doctor notices the combination of facial features, developmental delay, hearing loss, and skeletal problems. The initial step in laboratory testing is usually a urine screening that detects elevated levels of mannose-rich oligosaccharides. If that screening is suggestive, the diagnosis is confirmed by measuring alpha-mannosidase enzyme activity in white blood cells. An enzyme level below 0.54 nmol/min/mg protein is consistent with the diagnosis.
Genetic testing of the MAN2B1 gene can identify the specific mutation involved. This is especially valuable for family planning, because once a mutation is known, relatives can be tested to determine whether they are carriers.
Enzyme Replacement Therapy
The first targeted treatment for alpha mannosidosis is an enzyme replacement therapy called velmanase alfa, marketed as Lamzede. It is a lab-made version of the missing alpha-mannosidase enzyme. Given as a weekly intravenous infusion at a dose based on body weight, it supplements the body’s deficient enzyme supply and helps clear the accumulated oligosaccharides from tissues.
Lamzede was approved in Europe in March 2018 and later received FDA approval in the United States, making it the first enzyme replacement therapy available for this condition. It carries an orphan drug designation, reflecting the rarity of the disease. The therapy is approved for non-central nervous system symptoms, meaning it can improve organ and tissue function but has limited ability to cross the blood-brain barrier and address neurological decline directly.
Patients receiving the infusion typically reach peak drug levels about 1.8 hours after the infusion begins. Because the treatment is lifelong, families should expect a commitment to regular weekly infusions, usually at a specialized medical center.
Stem Cell Transplantation
Hematopoietic stem cell transplantation (bone marrow transplant) is the other major treatment option, and it is generally considered for younger children because donor-derived cells can take up residence throughout the body and produce the missing enzyme on an ongoing basis. Unlike enzyme replacement, transplanted cells can potentially deliver enzyme to the brain.
A study of 21 children who underwent transplantation found encouraging results. The median age at transplant was 3.9 years, and primary engraftment succeeded in 17 of the 21 patients. The four who did not engraft on the first attempt underwent a second transplant successfully. No patients in the study died during follow-up.
Clinical improvements were measurable. Liver enlargement dropped from 40% of patients before the transplant to 10% afterward. Recurrent infections fell from 62% to 30%. Hearing problems improved somewhat, going from 85% to 65%. Developmental delays, however, tended to persist: 85% of children with available data still showed at least mild delays after the transplant, though there were signs that earlier treatment led to better outcomes.
Living With Alpha Mannosidosis
Day-to-day management involves a team of specialists addressing the condition’s many facets. Hearing aids or cochlear implants may be needed for hearing loss. Cataracts can require surgical correction. Orthopedic care helps manage joint deterioration and skeletal deformities, and physical therapy is important for maintaining mobility and countering muscle weakness. Speech therapy supports communication development, particularly in children. Because psychiatric episodes can occur, mental health monitoring is part of comprehensive care, especially around periods of stress or major life changes.
Life expectancy varies significantly by severity. In the severe form, death can occur within the first decade of life. For those with milder disease, the outlook is considerably better. A review of published patient data found that 72% of individuals with alpha mannosidosis were still alive after age 41, and the median age at death among patients tracked by clinicians was 45 years. These numbers reflect a mix of disease severities and treatment eras, so outcomes for children diagnosed and treated early today may be better still.
How Common Is It
Alpha mannosidosis is extremely rare. The estimated global incidence is approximately 1 in 785,000 live births. Rates vary by population: roughly 1 in 167,000 among Europeans of Finnish descent and about 1 in 432,000 among East Asians. Because the condition is autosomal recessive and requires two copies of a defective gene, many carriers exist in the population without ever knowing it, and the disease can appear in families with no prior history.